
The Journey of the Unknown Primary in the HPV Era: Evaluation, Treatment, Surveillance and Management of Oligometastatic Disease
Management of unknown primary head and neck squamous cell carcinomas has evolved as the incidence of p16 positive disease among head and neck cancer patients has increased. This activity discusses the diagnostic steps to identify a primary site and treatment of patients where primary is and is not identified. We also discuss post-treatment surveillance of p16 positive patients including the role of TTMV-HPV DNA as a surveillance tool. Finally, we discuss management options for patients with oligometastatic disease.
Topics:
- Work-up and Treatment of Unknown Primary p16 Positive Head and Neck Squamous Cell Carcinoma
Jessica Wen-chia Lee, MD - Surveillance of p16 Positive Head and Neck Squamous Cell Carcinoma: Examination, Imaging and Biomarkers
Edina C. Wang, MD - Management of Metastatic HPV+ Head and Neck Cancers
Musaddiq Javvad Awan, MD - Q and A
Virginia Diavolitsis, MD - Moderator
Full Panel
This activity is available from April 7, 2026, through 11:59 p.m. Eastern time on April 6, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of radiation oncologists, physicists, radiation therapists, radiation dosimetrists, residents and ear, nose and throat specialists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the steps in evaluation of a patient with an unknown primary p16 positive head and neck squamous cell carcinoma and management of patients where primary site is not identified.
- Discuss the role of TTMV-HPV DNA as a surveillance tool for patients with p16 positive head and neck squamous cell carcinoma.
- Describe management options for patients with oligometastatic p16 positive head and neck squamous cell carcinoma.
Course summary
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Moderator:
- Virginia Diavolitsis, MD, is employed by The Ohio State University and Riverside Radiation Oncology, Inc. Dr. Diavolitsis has no relevant financial relationship with ineligible companies to disclose.
Speakers:
- Jessica Wen-chia Lee, MD, is employed by the Mid-Atlantic Permanente Medical Group. Dr. Lee has no relevant financial relationship with ineligible companies to disclose.
- Edina C. Wang, MD, is employed by Duke University Medical Center. Dr. Wang has no relevant financial relationship with ineligible companies to disclose.
- Musaddiq Javvad Awan, MD, is employed by Medical College of Wisconsin. Dr. Awan receives research support from NIH and Genentech.
Planners:
- Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Activity Fees
This activity is included in the ASTRO Academy Subscription. To purchase the subscription beginning December 1, 2026, please go to the ASTRO Product Catalog.
ASTRO members and Academy subscribers must log in to the ASTRO Academy to view and receive the corresponding rate:
- Academy Subscriber: $0
- Member: $99
- Member-in-Training / Student Member / Postdoctoral Fellow Member: $49
- Nonmember: $149
Discounts
Please email ASTRO eLearning to inquire about the discounts below.
- If you are an ASTRO member residing in a low- or lower-middle-income economy country, as identified by the World Bank, you can receive a 50% discount off the activity fee.
- If you are an ASTRO member residing in an upper-middle-income economy country, as identified by the World Bank, you can receive a 25% discount off the activity fee.
Policies
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until the Activity expiration date, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Copyright of all aspects of ASTRO Academy Content, including recordings and/or reproductions of sessions, programs, presentations, discussions and other scheduled events (“ASTRO Academy Content”) is owned by ASTRO. Only ASTRO reserves the rights to all ASTRO Academy Content, including to digitize, modify, alter, edit, adapt, create derivative works, display, publicly perform, exhibit, transmit, broadcast, reproduce, exploit, sell, rent license, otherwise use, and permit others to use, such ASTRO Academy Content. Photographing, filming, taping, recording or any form of capture or reproduction in any medium of any aspect of ASTRO Academy Content, including, but not limited to the programs, presentations, material, sessions, and discussions, or on the Academy platform are strictly forbidden without written authorization from ASTRO.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.

Facebook
X
LinkedIn
Forward